There are multiple treatment options for presbyopia, from simple solutions such as reading glasses or contact lenses to more complex procedures such as refractive eye surgery. Presbyopia is the ...

You can’t prevent or reverse presbyopia with natural treatments. However, quitting smoking (if you smoke) and upping your intake of vitamins A, C, and E may improve your eye health. Presbyopia is a ...

Presbyopia is an eye condition that causes a reduced ability to see things up close. It occurs when the eye’s lens stops focusing light correctly on the retina and usually develops later in life. The ...

Please provide your email address to receive an email when new articles are posted on . Staff can be trained to collect information about patients’ lifestyles from ...

As people age, many develop presbyopia — age-related farsightedness that makes it hard to read things at close range — and may turn to reading glasses. But new research suggests another option may be ...

Credit: Orasis Pharmaceuticals. The product is expected to be available in the first half of 2024. The Food and Drug Administration (FDA) has approved Qlosi ™ (pilocarpine hydrochloride ophthalmic ...

DelveInsight’s “Presbyopia Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Presbyopia pipeline landscape. It covers the Presbyopia ...

On Thursday, the U.S. Food and Drug Administration approved LENZ Therapeutics, Inc.’s (NASDAQ:LENZ) VIZZ (aceclidine ophthalmic solution, previously known as LNZ100) 1.44%, the first and only ...

LENZ Therapeutics, Inc.'s aceclidine offers superior duration and safety for presbyopia, addressing Vuity's shortcomings and targeting a large, underserved US market. I expect strong initial ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- Two ...

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Presbyopia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...

The phase 3 NEAR-1 and NEAR-2 trials included 613 patients aged 45 to 64 years with presbyopia. Positive results were announced from two phase 3 trials evaluating the efficacy and safety of CSF-1, a ...